That would be a BIG move Riz, wouldn't it? Yes, everyone

New Post Public Reply Private Reply Replies (0) Message Board
MGK_2 Riztheinvestor #130632
588
That would be a BIG move Riz, wouldn't it?
Yes, everyone is expendable, but at what cost?

Recknor was/is in the heart of it. In the midst of the Raw Data, aggregating it.
Working with the CRO for PharmacoVigilance, he knows the depths and the details of what Amarex did wrong.

Sure, there is the CRO there, there is now 3x external auditors who also know, even Sidley Austin knows it, but also referring back to conference call 6/28/22:

Quote:
18:50 Antonio Migliarese: Thanks Scott. ... all hands on deck effort. ...we have a strong project team in place, which is led internally, by ... Joe Meidling and ...Bernie Cunningham. We've additionally engaged in CRO, clinical research organization ... in the areas of pharmacovigilance, safety data based management analysis. ... regulatory consulting firm that is assisting us with the preparation and review of the various regulatory communication, and lastly we have the data to work with an overall regulatory strategy advising group. This group is one of the most reputable at being regulatory consulting firms led by former FDA regulators.

... Furthermore, this allows us to identify opportunities to bring in additional resources and where if possible to expedite time.

and we have learned that a total of 4 external auditors were brought in.

So, my point here is that Chris Recknor has the information, but there are a few internal people who have taken responsibility for that data. Likely Meidling and Cunningham. The pertinent points about Amarex's failings have been transferred to these individuals and to Sidley Austin.

What about his work for NASH. Recknor was in the heart of that. He was determining the findings and the interpretation of the 350 NASH and 700mg NASH data. 350 was looking great and it still does. 700HM looks great, but not 700mg. Ohm thinks CRO botched the laboratory analysis. Could be.

Recknor was looking into it further. But his time was consumed with Amarex past 6 months.
EASL was quite a deal according to Kelly. Noureddin will be stating to what extent hopefully on 12/7.

I believe Recknor was onto something with 700mg NASH, but not sure if his findings were communicated to Noureddin.

What you are hinting towards, a Buy Out or a partnership is possible which means that the company doing the buy out feels they have already what Recknor has and they can take his data and work out the answer for them selves.

In any event, we have Cyrus Arman who is doing the decision making. At a time when CytoDyn is at nearly its wits end, are you going to cut one of your top guys and cut your knowledge base of the molecule and how it works if that information would also be sacrificed. I think if this decision was made to let Recknor go, it would have meant that everything Recknor provided for the company would remain, and that it would only mean that Chris needed to leave for what ever reason, personal or business related.

Cyrus made the decision if in fact a decision was made and because of the person making the decision, I respect it as the way forward.

---
Now if I had to guess as to a reason why Recknor may have left, it would have to do with a disagreement he could have made with Arman about not submitting the BLA. I'm definitely not saying that Recknor did that, I just venturing up a hypothetical guess as to what may have led to this given how hard he worked on aggregating the raw data and determining first hand that leronlimab was safe and effective regardless of how pitiful the quality of the trials were conducted.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 255

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 266

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 176

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 113

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 59

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Flora Growth Corp Sees 6% Surge in After-Hours Performance

Updated Category News Views 87

A Surge in After-Hours Trading for Flora Growth Corp Flora Growth Corp. (NASDAQ: FLGC) recently demonstrated significant volatility by surging 5.98% to $10.55 during after-hours trading. This movement came not long after closing at $9.96, which marked an increase of 3.59% earlier that day. Insights from Recent SEC Filing Regulation A Filing In a notable move, Flora Growth...

Continue Reading
Qubs Introduces Qubitunes, A New Interactive Audio Experience

Updated Category News Views 205

Qubs Launches Qubitunes for Creative Play Qubs has unveiled an exciting new product, Qubitunes, which has already won the 'Top Toy' award in the startup category at a prestigious Toy Fair. This innovative toy is set to transform playtime for children by offering a unique platform where they can express their creativity and dive into their own audio storytelling...

Continue Reading
Asyad Group's Expert Transport of Heavy Cryogenic Tank

Updated Category News Views 126

Asyad Group's Successful Transport of Cryogenic Tank Asyad Group has recently completed a remarkable international transport operation, successfully moving a 115 metric ton pressurized cryogenic tank from Northern India to a major destination in Saudi Arabia. This endeavor highlights the Group's expertise in cross-border logistics. A Journey of Precision The transport...

Continue Reading
Famous Toastery Launches Holiday Fundraising Efforts

Updated Category News Views 134

Famous Toastery's Compassionate Campaign for Local Communities The Famous Toastery, known for its delightful breakfast and brunch offerings, is stepping up this holiday season with a noble initiative aimed at fighting hunger. This renowned franchise is collaborating with Feeding the Carolinas, encouraging guests to make donations that will significantly impact individuals...

Continue Reading
Jiayin Group's Upcoming Earnings Call Set for November 25, 2025

Updated Category News Views 190

Jiayin Group Inc. Announces Q3 2025 Financial Results Release Jiayin Group Inc. (NASDAQ: JFIN), a prominent fintech platform in China, has shared significant news that it will unveil its unaudited financial outcomes for the third quarter of 2025. This crucial announcement is set to occur before the U.S. markets open on November 25, 2025. The anticipation surrounding these...

Continue Reading